CorVel (NASDAQ: CRVL) and Cancer Genetics (NASDAQ:CGIX) are both small-cap business services companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
Risk & Volatility
CorVel has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Cancer Genetics has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.
This table compares CorVel and Cancer Genetics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|CorVel||$518.69 million||1.89||$29.47 million||$1.82||28.54|
|Cancer Genetics||$27.05 million||1.95||-$15.80 million||($0.82)||-2.32|
CorVel has higher revenue and earnings than Cancer Genetics. Cancer Genetics is trading at a lower price-to-earnings ratio than CorVel, indicating that it is currently the more affordable of the two stocks.
This table compares CorVel and Cancer Genetics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and price targets for CorVel and Cancer Genetics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cancer Genetics has a consensus target price of $6.00, indicating a potential upside of 215.79%. Given Cancer Genetics’ higher possible upside, analysts clearly believe Cancer Genetics is more favorable than CorVel.
Insider and Institutional Ownership
46.1% of CorVel shares are held by institutional investors. Comparatively, 18.0% of Cancer Genetics shares are held by institutional investors. 51.0% of CorVel shares are held by insiders. Comparatively, 21.3% of Cancer Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
CorVel beats Cancer Genetics on 9 of the 13 factors compared between the two stocks.
CorVel Company Profile
CorVel Corporation (Corvel) is a provider of workers’ compensation solutions for employers, third party administrators, insurance companies and government agencies. The Company offers its services as a bundled solution, which includes claims management, as a standalone service, or as add-on services to existing customers. The Company offers its services as a bundled solution, which includes claims management, as a standalone service, or as add-on services to existing customers. The Company’s network solutions include bill review, preferred provider organization (PPO) management, professional review, provider reimbursement, pharmacy services, directed care services, medicare solutions and clearinghouse services. The Company’s patient management services include claims management, case management, 24/7 nurse triage, utilization management, vocational rehabilitation, life care planning, disability management, liability claims management and auto claims management.
Cancer Genetics Company Profile
Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information. Its Select One Clinical Trials program provides a range of integrated and dynamic clinical trial services for both oncology and non-oncology genetic testing for Phase I-III trials along with ancillary services, including bioinformatics, biorepository and trials logistic support. The Company is developing a global footprint with locations in the United States, India and China. It also offers a portfolio of genotyping services, with access to over 400 validated genotyping assays, including Phase I and Phase II drug metabolizing enzymes, transporters, and receptors, and over 30 validated gene expression assays.
Receive News & Ratings for CorVel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorVel and related companies with MarketBeat.com's FREE daily email newsletter.